The estimated Net Worth of Dennis S Meteny is at least $1.13 Milion dollars as of 12 July 2022. Mr. Meteny owns over 6,022 units of Angiodynamic Inc stock worth over $895,713 and over the last 20 years he sold ANGO stock worth over $0. In addition, he makes $232,008 as Independent Director at Angiodynamic Inc.
Dennis has made over 10 trades of the Angiodynamic Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 6,022 units of ANGO stock worth $96,051 on 12 July 2022.
The largest trade he's ever made was exercising 15,500 units of Angiodynamic Inc stock on 16 May 2014 worth over $170,500. On average, Dennis trades about 2,557 units every 113 days since 2004. As of 12 July 2022 he still owns at least 120,716 units of Angiodynamic Inc stock.
You can see the complete history of Mr. Meteny stock trades at the bottom of the page.
Dennis S. Meteny serves as Independent Director of the Company. Since January 2014, Mr. Meteny has been a director of Blue Water Growth LLC, a global business consulting firm with services including mergers and acquisitions, private capital solutions, product distribution, outsourcing, and a wide variety of business advisory services for its Western and Asian clients. From 2006 to January 2014, Mr. Meteny was President and Chief Executive Officer of Cygnus Manufacturing Company LLC, a privately held manufacturer of medical devices, health and safety components, and high precision transportation, aerospace and industrial products. From 2003 to 2006, Mr. Meteny was an Executive-in-Residence at the Pittsburgh Life Sciences Greenhouse, a strategic economic development initiative of the University of Pittsburgh Health System, Carnegie Mellon University, the University of Pittsburgh, the State of Pennsylvania and local foundations. From 2001 to 2003, he was President and Chief Operating Officer of TissueInformatics, Inc., a privately held company engaged in the medical imaging business. From 2000 to 2001, Mr. Meteny was a business consultant to various technology companies. Prior to that, Mr. Meteny spent 15 years in several executive-level positions, including as President and Chief Executive Officer, from 1994 to 1999, of Respironics, Inc. a cardio-pulmonary medical device company. Mr. Meteny holds a B.S. Degree in Accounting from The Pennsylvania State University and an MBA from the University of Pittsburgh. Mr. Meteny is the Chairman of our Audit Committee.
As the Independent Director of Angiodynamic Inc, the total compensation of Dennis Meteny at Angiodynamic Inc is $232,008. There are 12 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.
Dennis Meteny is 67, he's been the Independent Director of Angiodynamic Inc since 2004. There are no older and 26 younger executives at Angiodynamic Inc.
Dennis's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman a Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: